NASDAQ:SYNHSyneos Health Stock Price, Forecast & News

$61.09

+0.10 (+0.16 %)

(As of 06/1/2020 01:13 PM ET)

Add

Compare

Today's Range

$60.51

Now: $61.09▼

$61.90

50-Day Range

$46.56

MA: $53.88▼

$62.43

52-Week Range

$30.02

Now: $61.09▼

$74.25

Volume13,969 shs

Average Volume454,322 shs

Market Capitalization$6.36 billion

P/E Ratio33.02

Dividend YieldN/A

Beta1.79

Syneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. The Commercial Solutions segment provides commercialization services, including medication adherence, communications, and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.

Beat the Market (BTM) Rank^™

2.3 Analyst's Opinion

Consensus Rating
Syneos Health has received a consensus rating of Buy. The company's average rating score is 2.64, and is based on 7 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $60.45, Syneos Health has a potential downside of 1.0% from its current price of $61.09.
Amount of Analyst Coverage
Syneos Health has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.8 Community Rank

Outperform Votes
Syneos Health has received 515 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Syneos Health has received 413 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Syneos Health has received 55.50% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Syneos Health and other stocks. Vote “Outperform” if you believe SYNH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SYNH will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Syneos Health does not currently pay a dividend.
Dividend Growth
Syneos Health does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Syneos Health insiders have sold 84.09% more of their company's stock than they have bought. Specifically, they have bought $178,256.00 in company stock and sold $328,144.00 in company stock.
Percentage Held by Insiders
Only 0.44% of the stock of Syneos Health is held by insiders.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Syneos Health are expected to grow by 34.57% in the coming year, from $2.43 to $3.27 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Syneos Health is 33.02, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.50.
Price to Earnings Ratio vs. Sector
The P/E ratio of Syneos Health is 33.02, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.38.
Price to Book Value per Share Ratio
Syneos Health has a P/B Ratio of 2.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.27 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Commercial physical research

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:SYNH

Previous Symbol

CUSIPN/A

CIK1610950

Webwww.syneoshealth.com

Phone919-876-9300

Debt

Debt-to-Equity Ratio1.03

Current Ratio1.23

Quick Ratio1.23

Price-To-Earnings

Trailing P/E Ratio33.02

Forward P/E Ratio25.14

P/E GrowthN/A

Sales & Book Value

Annual Sales$4.68 billion

Price / Sales1.36

Cash Flow$5.21 per share

Price / Cash Flow11.73

Book Value$29.19 per share

Price / Book2.09

Profitability

EPS (Most Recent Fiscal Year)$2.83

Net Income$131.26 million

Net Margins4.13%

Return on Equity10.33%

Return on Assets4.05%

Miscellaneous

Employees24,000

Outstanding Shares104,170,000

Market Cap$6.36 billion

Next Earnings Date8/4/2020 (Estimated)

OptionableOptionable

Receive SYNH News and Ratings via Email

Sign-up to receive the latest news and ratings for SYNH and its competitors with MarketBeat's FREE daily newsletter.

Syneos Health (NASDAQ:SYNH) Frequently Asked Questions

How has Syneos Health's stock been impacted by COVID-19 (Coronavirus)?

Syneos Health's stock was trading at $57.30 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SYNH stock has increased by 6.6% and is now trading at $61.09. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Syneos Health?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Syneos Health.

When is Syneos Health's next earnings date?

Syneos Health is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Syneos Health.

How were Syneos Health's earnings last quarter?

Syneos Health Inc (NASDAQ:SYNH) released its quarterly earnings results on Thursday, April, 30th. The company reported $0.68 EPS for the quarter, beating the Zacks' consensus estimate of $0.64 by $0.04. The company had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.14 billion. Syneos Health had a return on equity of 10.33% and a net margin of 4.13%. The company's revenue for the quarter was up 4.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.59 earnings per share. View Syneos Health's earnings history.

What price target have analysts set for SYNH?

11 brokerages have issued twelve-month target prices for Syneos Health's shares. Their forecasts range from $42.00 to $82.00. On average, they expect Syneos Health's share price to reach $60.45 in the next year. This suggests that the stock has a possible downside of 1.0%. View analysts' price targets for Syneos Health.

Has Syneos Health been receiving favorable news coverage?

Media headlines about SYNH stock have been trending somewhat positive this week, according to InfoTrie. The research firm scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Syneos Health earned a coverage optimism score of 1.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutSyneos Health.

Are investors shorting Syneos Health?

Syneos Health saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 6,030,000 shares, an increase of 5.1% from the April 30th total of 5,740,000 shares. Based on an average daily volume of 812,200 shares, the days-to-cover ratio is presently 7.4 days. Currently, 9.7% of the shares of the company are short sold. View Syneos Health's Current Options Chain.

Who are some of Syneos Health's key competitors?

Some companies that are related to Syneos Health include Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Icon (ICLR), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), PRA Health Sciences (PRAH), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Pieris Pharmaceuticals (PIRS) and Luna Innovations (LUNA). View all competitors.

What other stocks do shareholders of Syneos Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include Alibaba Group (BABA), NVIDIA (NVDA), Netflix (NFLX), Square (SQ), AT&T (T), CVS Health (CVS), Gilead Sciences (GILD), UnitedHealth Group (UNH), Visa (V) and Delta Air Lines (DAL).

Who are Syneos Health's key executives?

Syneos Health's management team includes the following people:

Mr. Alistair Macdonald, CEO & Director (Age 49)
Mr. Jason M. Meggs, Chief Financial Officer (Age 43)
Mr. Jonathan Olefson, Gen. Counsel & Corp. Sec. (Age 43)
Mr. Michael Adam Bell, Consultant (Age 63)
Mr. Robert Parks, Exec. VP & Chief Accounting Officer

What is Syneos Health's stock symbol?

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

Who are Syneos Health's major shareholders?

Syneos Health's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.18%), Clearbridge Investments LLC (3.37%), ArrowMark Colorado Holdings LLC (2.32%), Mackenzie Financial Corp (2.15%), State Street Corp (1.90%) and JPMorgan Chase & Co. (1.79%). Company insiders that own Syneos Health stock include Alistair Macdonald, H Lee Equity Fund Vi Thomas, Jason M Meggs, Jonathan Olefson, Michelle Keefe, Paul Colvin and Robert Parks. View institutional ownership trends for Syneos Health.

Which institutional investors are selling Syneos Health stock?

SYNH stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Mackenzie Financial Corp, BlackRock Inc., Principal Financial Group Inc., Clearbridge Investments LLC, Nuveen Asset Management LLC, Magnetar Financial LLC, and Bank of New York Mellon Corp. Company insiders that have sold Syneos Health company stock in the last year include Michelle Keefe, and Robert Parks. View insider buying and selling activity for Syneos Health.

Which institutional investors are buying Syneos Health stock?

SYNH stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., ArrowMark Colorado Holdings LLC, JPMorgan Chase & Co., AQR Capital Management LLC, Massachusetts Financial Services Co. MA, Geode Capital Management LLC, and Mutual of America Capital Management LLC. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs, Jonathan Olefson, and Paul Colvin. View insider buying and selling activity for Syneos Health.

How do I buy shares of Syneos Health?

Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Syneos Health's stock price today?

One share of SYNH stock can currently be purchased for approximately $61.09.

How big of a company is Syneos Health?

Syneos Health has a market capitalization of $6.36 billion and generates $4.68 billion in revenue each year. The company earns $131.26 million in net income (profit) each year or $2.83 on an earnings per share basis. Syneos Health employs 24,000 workers across the globe.

What is Syneos Health's official website?

The official website for Syneos Health is www.syneoshealth.com.

How can I contact Syneos Health?

Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The company can be reached via phone at 919-876-9300 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff